Resources from the same session
233MO - Ovarian function suppression in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial
Presenter: Sung Gwe Ahn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
234MO - Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: A nationwide cohort study
Presenter: Elise Dumas
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
235MO - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Sherene Loi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Invited Discussant 233MO, 234MO and 235MO
Presenter: Kevin Kalinsky
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
236MO - Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study
Presenter: Manon de Graaf
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
237MO - TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
Presenter: Miguel Martin Jimenez
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
238MO - PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
Presenter: Francois Cherifi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA14 - Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Presenter: Sabine Linn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA15 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Meghna Trivedi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA16 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Katia Khoury
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast